Description
Key Aspects of Cagrilintide:
- Mechanism of Action: As a long-acting amylin receptor agonist, it acts on the brain to reduce calorie intake and food cravings.
- Weight Loss Potential: In studies, it demonstrated significant efficacy alone and as a combination therapy.
- Combination Therapy (CagriSema): Cagrilintide is often paired with Semaglutide (creating “CagriSema”) for enhanced weight loss, aiming for greater reduction than existing GLP-1s alone.
- Administration: It is designed to be a once-weekly injection.
- Side Effects: Similar to other weight loss treatments, side effects may include mild injection site reactions, and potentially, gastrointestinal issues.
- Clinical Trials: Currently in late-stage Phase 3 trials (such as the REDEFINE program) to evaluate its long-term safety and efficacy.
- Dosage: Reconstitute with 2ml Bac water, starting dose 10 units subcutaneous injection once a week.
Cagrilintide represents a promising next-generation weight-loss strategy that operates via a different pathway than traditional GLP-1 drugs.
Research Use Only: Not for human or veterinary use.
